CDKN2A and glioma: In addition, the few existing human pediatric LGG xenograft models harbor genetic mutations (TP53/CDKN1A or CDKN2A/RB1 alterations) uncharacteristic of these childhood gliomas, especially PAs, which were specifically introduced to permit pediatric LGG cells to escape cellular senescence [55, 62].